Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE
Ascelia Pharma AB (publ) (ticker: ACE) today published its interim financial report for Q1-2020 (January – March 2020), which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN Q1-2020 · First patient enrolled in Mangoral’s Phase 3 study SPARKLE · Additional clinical sites opened for patient enrolment · Ascelia Pharma wins the award as the best Life Science company in Malmö, Sweden SIGNIFICANT EVENTS AFTER THE PERIOD · Patent for Oncoral approved in Japan · First participant enrolled in the clinical